NCT03371849View on ClinicalTrials.gov

PK and Safety Study of HCP1102, HGP0813 and HGP1408

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

July 19, 2017

Primary Completion Date

August 3, 2017

Study Completion Date

August 3, 2017

Conditions
Healthy
Interventions
DRUG

montelukast and levocetirizine FDC

HCP1102

DRUG

Singulair + xyzal

HGP0813 + HGP1408

Trial Locations (1)

Unknown

Chonbuk National University Hospital, Jeonju

Sponsors
All Listed Sponsors
lead

Hanmi Pharmaceutical Company Limited

INDUSTRY

NCT03371849 - PK and Safety Study of HCP1102, HGP0813 and HGP1408 | Biotech Hunter | Biotech Hunter